Nymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Company's Manufacturi...
March 13 2019 - 9:30AM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to
announce the new appointment of Russell I. Thomson PhD, FRSC, as
the Company's Director of Quality and EU Qualified Person, for all
of Nymox's Chemistry, Manufacturing and Controls Operations.
Dr Thomson is an authority in the field of Quality Assurance and
Control in the Chemical and Pharmaceutical Industries.
Dr. Thomson is a Fellow of the Royal Society of
Chemistry (UK), a Chartered Chemist and Chairman of the Royal
Society of Chemistry Qualified Persons Assessors Panel. He
has worked in the pharmaceutical industry in positions including
Head of Quality and Director of QA and Regulatory Affairs, and as
Consultant Qualified Person at numerous large and small drug
manufacturing facilities in the EU and the US for over 20
years. Dr. Thomson was a Chartered Scientist with The Science
Council (UK) from 2004-2010 and Corporate Member of the South
African Chemical Institute from 1980-1999. He received his PhD in
Chemistry from the University of South Africa.
Dr. Paul Averback, CEO of Nymox, said, "Nymox
has had the significant benefit of Dr. Thomson's expertise and
extensive auditing activities of the Company's manufacturing
related activities during the past 8 years as Qualified Person in
the EU. We are extremely fortunate at this important stage in the
development of our first in class compound Fexapotide Triflutate to
have Dr. Thomson now join Nymox as Director of Quality and EU
Qualified Person, and he is now the Senior Director of our staff
involved in the important work of Quality Control and Quality
Assurance for Nymox's manufacturing activities in the U.S. and in
the EU. Russell is an authority on implementation of Quality
Assurance for Manufacturing in this sector, and brings to our
organization his vast knowledge and practical experience."
Nymox recently announced the publication of an
important peer review article entitled "Efficacy and Safety of
Fexapotide Triflutate in Outpatient Medical Treatment of Male Lower
Urinary Tract Symptoms Associated with Benign Prostatic
Hyperplasia", authored by Neal Shore MD, Ronald Tutrone MD, and
Claus Roehrborn MD, in Therapeutic Advances in Urology 219, 11,
1-16. The report reviews the progress in the development of
Fexapotide Triflutate which is Nymox's first-in-class new molecular
approach to managing BPH symptoms.
The Company will host a shareholder
teleconference on March 25 to update current progress in business
and regulatory submission activities.
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2017, and its Quarterly Reports.
For Further Information
Contact:Erik DanielsenNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024